Deutsche Bank Aktiengesellschaft Has Lowered Expectations for Hikma Pharmaceuticals (LON:HIK) Stock Price

Key Points

• Deutsche Bank Aktiengesellschaft has reduced its price target for Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850, maintaining a "buy" rating with a potential upside of 57.91% from the previous closing price.
• JPMorgan Chase & Co. also lowered its target price for Hikma Pharmaceuticals to GBX 2,500 while keeping an "overweight" rating, signifying cautious sentiment towards the stock.
• Recent insider activity includes a notable purchase of 200,000 shares by insider Mazen Darwazah at an average price of GBX 1,756, suggesting confidence in the company's future.

Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its price target cut by equities researchers at Deutsche Bank Aktiengesellschaft from GBX 3,100 ($41.87) to GBX 2,850 ($38.50) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage currently has a "buy" rating on the stock. Deutsche Bank Aktiengesellschaft's target price would indicate a potential upside of 58.19% from the stock's previous close.

A number of other research analysts have also recently weighed in on HIK. Jefferies Financial Group reiterated a "buy" rating and set a GBX 2,600 ($35.12) price objective on shares of Hikma Pharmaceuticals in a research report on Thursday, August 7th. JPMorgan Chase & Co. dropped their price target on shares of Hikma Pharmaceuticals from GBX 2,600 ($35.12) to GBX 2,500 ($33.77) and set an "overweight" rating for the company in a research note on Friday, August 8th.

Hikma Pharmaceuticals Trading Up 0.5%

Shares of LON:HIK traded up GBX 8.29 ($0.11) during trading on Tuesday, hitting GBX 1,801.59 ($24.34). The company had a trading volume of 893,383 shares, compared to its average volume of 1,028,254. The stock has a market cap of £5.00 billion, a price-to-earnings ratio of 17.68, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a one year low of GBX 1,690 ($22.83) and a one year high of GBX 2,360 ($31.88). The company has a fifty day simple moving average of GBX 1,970.88 and a two-hundred day simple moving average of GBX 2,030.87. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27.

Insider Activity

In related news, insider Mazen Darwazah bought 200,000 shares of the company's stock in a transaction on Thursday, August 7th. The shares were acquired at an average cost of GBX 1,756 ($23.72) per share, for a total transaction of £3,512,000 ($4,744,022.69). Also, insider Said Darwazah sold 13,863 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of GBX 2,138 ($28.88), for a total transaction of £296,390.94 ($400,365.99). Company insiders own 30.54% of the company's stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.